Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day
control group:conventional therapy
Sponsors
The First Hospital of Peking University
Eligibility
Sex/Gender
All
Age
16 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with novel coronavirus infection who agreed to participate in this trial and signed the informed consent form. The diagnose criteria was according to Diagnostic and treatment protocol of COVID-19 pneumonia published by Chinese General Office of National Health Committee(6th and further edition).
Exclusion criteria
Exclusion criteria: Patients who is enrolled in other clinical trial who had diagnosed as macular degeneration of retinawere or defects of visual field; who was allergic to 4-aminoquinoline compounds or is prescribed any drug had interactions with hydrocholoroquine emergency or critically ill patients who can not received oral drugs pregnancy or lactation severe heart disease, digestive disease,neurological or ocular disease,or porphyrin; WBC less than 2.0*10^9/L,hemoglobin 60g/L,liver enzyme or creatine higher than 3 times of ULT,or heart marker elevated, unsuitable to participate this trial by investigator or in other special circumstances.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| oxygen index;max respiratory rate;lung radiography;count of lymphocyte;temperature;other infection;time when the nuleic acid of the novel coronavirus turns negative;prognosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood pressure;heart rate;immunoglobin level; | — |
Countries
China
Contacts
Public ContactZhuoli Zhang
The First hospital of Peking University
Outcome results
None listed